The Acquisition of Drugs and Biologics for Chemical and Biological Warfare Defense
Department of Defense Interactions with the Food and Drug Administration
Download
Download eBook for Free
| Format | File Size | Notes |
|---|---|---|
| PDF file | 0.3 MB | Use Adobe Acrobat Reader version 10 or higher for the best experience. |
Purchase
Purchase Print Copy
| Format | List Price | Price | |
|---|---|---|---|
| Add to Cart | Paperback100 pages | $20.00 | $16.00 20% Web Discount |
The 1990-1991 Gulf War made clear the U.S. Department of Defense’s (DoD’s) need to effectively acquire drugs and biologics, mainly vaccines, as American troops faced the real threat of chemical and biological warfare (CBW) agents being used in combat. More than a decade after the war, DoD still experiences acute obstacles in obtaining CBW defense supplies — most recently magnified by the department’s attempt to acquire the anthrax vaccine for all its personnel. Key to this acquisition success for the department is its relationship with the U.S. Food and Drug Administration (FDA), which oversees compliance of all licensed drugs and the testing of new medications and vaccines. The DoD-FDA relationship specifically involves matters of licensing, the use of Investigational New Drugs in combat, and the compliance of drug and biologics producers with manufacturing requirements. How can effective communication and procedures improve between the two government entities? The authors recommend such changes as centralizing authority for DoD-FDA relations for CBW drugs and biologics in the Office of the Secretary of Defense and implementing training on FDA regulations for DoD acquisition personnel. Such progress is crucial as the U.S. military faces a variety of new threats in the post-9/11 world.
Table of Contents
Chapter One
Introduction
Chapter Two
The Challenges of Acquisition
Chapter Three
The Industrial Model
Chapter Four
Summary and Recommendations
Appendix
Private Providers of FDA-Related Education and Training
Research conducted by
The research described in this report was sponsored by the Office of the Secretary of Defense (OSD). The research was conducted jointly by RAND Health's Center for Military Health Policy Research and the Forces and Resources Policy Center of the RAND National Defense Research Institute, a federally funded research and development center supported by the OSD, the Joint Staff, the unified commands, and the defense agencies.
This report is part of the RAND Corporation Monograph report series. The monograph/report was a product of the RAND Corporation from 1993 to 2003. RAND monograph/reports presented major research findings that addressed the challenges facing the public and private sectors. They included executive summaries, technical documentation, and synthesis pieces.
This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to this product page is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial purposes. For information on reprint and reuse permissions, please visit www.rand.org/pubs/permissions.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.